The ClinGen Evidence Repository is an FDA-recognized human genetic variant database containing expert-curated assertions regarding variants' pathogenicity and supporting evidence summaries. [Disclaimer]
  • There was no gene found in the curated document received from the VCI/VCEP
  • Gene listed was thus derived from ClinVar and/or CAR
  • The variant label for this record ("m.14482C>G") does not appear to be in HGVS format


Variant: m.14482C>G

CA344824

65513 (ClinVar)

Gene: MT-ND6
Condition: mitochondrial disease
Inheritance Mode: Mitochondrial inheritance
UUID: 80e94925-06b6-4d9b-bc32-b106d95802aa
Approved on: 2022-07-11
Published on: 2023-03-29

HGVS expressions

NC_012920.1:m.14482C>G
J01415.2:m.14482C>G
ENST00000361681.2:n.192G>C

Likely Pathogenic

The Expert Panel has overridden the computationally generated classification - "Uncertain Significance - Insufficient Evidence"
Met criteria codes 4
PM5 PM2_Supporting PS1 PP3
Not Met criteria codes 5
PM6 PS3 PS2 PS4 PP1

Evidence Links 0

Expert Panel

Criteria Specification Information

Criteria Specification: ClinGen Mitochondrial Disease Nuclear and Mitochondrial Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines Version 1_mtDNA

Criteria Specification Approval History
Criteria Specifications for this VCEP
Evidence submitted by expert panel
Mitochondrial Diseases VCEP
The m.14482C>G (p.M64I) variant in MT-ND6 has been reported in one proband from an extended consanguineous kindred with primary mitochondrial disease. The predominant feature in this family was bilateral optic atrophy consistent with Leber Hereditary Optic Neuropathy (LHON). The variant was present at homoplasmy in affected and unaffected individuals from this family and, when affected, the age of onset was early adulthood (PMID: 9443868). It appears some individuals from this family were reported multiple times (PMIDs: 21887510, 8742999). There are no reported de novo occurrences of this variant to our knowledge. The variant was homoplasmic in family members of the only reported proband, precluding consideration for segregation evidence. This variant is absent in the GenBank dataset, Helix dataset, and gnomAD v3.1.2 (PM2_supporting). Another variant at this nucleotide position leading to the same amino acid change was classified as likely pathogenic by this expert panel, m.14482C>A (p.M64I, PS1). Furthermore, a different variant at this amino acid position leading to a different amino acid change is one of the most common causes of LHON and is a known pathogenic variant, m.14484T>C (p.M64V, PM5). The computational predictor APOGEE gives a consensus rating of pathogenic with a score of 0.96 (Min=0, Max=1), which predicts a damaging effect on gene function (PP3). There are no cybrid studies, single fiber studies, or other functional assays reported for this variant. In summary, this variant meets criteria to be classified as likely pathogenic for primary mitochondrial disease inherited in a mitochondrial manner. We note that one expert on this panel felt uncertain significance was a more appropriate classification given the only reported family was consanguineous and nuclear genetic etiologies were not assessed. This classification was approved by the NICHD/NINDS U24 ClinGen Mitochondrial Disease Variant Curation Expert Panel on July 11, 2022. Mitochondrial DNA-specific ACMG/AMP criteria applied (PMID: 32906214): PM2_supporting, PS1, PM5, PP3.
Met criteria codes
PM5
Furthermore, a different variant at this amino acid position leading to a different amino acid change is one of the most common causes of LHON and is a known pathogenic variant, m.14484T>C (p.M64V, PM5).
PM2_Supporting
This variant is absent in the GenBank dataset, Helix dataset, and gnomAD v3.1.2 (PM2_supporting).
PS1
Another variant at this nucleotide position leading to the same amino acid change was classified as likely pathogenic by this expert panel, m.14482C>A (p.M64I, PS1).
PP3
The computational predictor APOGEE gives a consensus rating of pathogenic with a score of 0.96 (Min=0, Max=1), which predicts a damaging effect on gene function (PP3).
Not Met criteria codes
PM6
There are no reported de novo occurrences of this variant to our knowledge.
PS3
There are no cybrid studies, single fiber studies, or other functional assays reported for this variant.
PS2
There are no reported de novo occurrences of this variant to our knowledge.
PS4
The m.14482C>G (p.M64I) variant in MT-ND6 has been reported in one proband from an extended consanguineous kindred with primary mitochondrial disease. The predominant feature in this family was bilateral optic atrophy consistent with Leber Hereditary Optic Neuropathy (LHON). The variant was present at homoplasmy in affected and unaffected individuals from this family and, when affected, the age of onset was early adulthood (PMID: 9443868). It appears some individuals from this family were reported multiple times (PMIDs: 21887510, 8742999).
PP1
The variant was homoplasmic in family members of the only reported proband, precluding consideration for segregation evidence.
The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.
¤ Powered by BCM's Genboree.